MediLumine

MediLumine, founded in 2013 and headquartered in Canada, operates in the Biotechnology industry. The company focuses on delivering high-quality imaging and research tools aimed at supporting life sciences industries in the discovery of cures, living up to its slogan: "Imaging and Research Tools to Help Find Cures."

MediLumine specializes in providing cutting-edge preclinical imaging solutions through its innovative product lines. The PRISM™ series is noteworthy for its advanced in vivo imaging systems tailored for tracking physiological changes during therapeutic research, benefiting universities and pharmaceutical companies alike. The company's Fenestra® and Mvivo™ contrast agents notably enhance imaging in micro-CT applications, facilitating critical research in liver diseases, tumor burden quantification, and cell tracking.

With a strong commitment to advancing preclinical research, MediLumine presents a strategic opportunity for investors seeking to make an impact in the biotechnology sector. No recent investments have been disclosed, positioning it as a promising target for future funding rounds.